Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Term Empagliflozin for Diuretic-Resistant Cirrhotic Ascites
jRCT1031250786Recruiting
- Sponsor
- Ministry of Health, Labour and Welfare
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in Cirrhosis, ascites and type 2 diabetes mellitus (T2DM), sponsored by Ministry of Health, Labour and Welfare. Primary endpoint: Primary: Change in body weight from baseline to Week 4. Started Mar 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
Cirrhosisascitestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1031250786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250786.